UNIMED AND TAP JOIN FORCES TO CO-PROMOTE ANDROGEL®

TAP Pharmaceutical Products Inc. and Unimed Pharmaceuticals, Inc. announced an agreement to co-promote AndroGel® 1% (testosterone gel) CIII in the United States. The U.S. Food and Drug Administration (FDA) approved AndroGel® in February 2000 to treat conditions associated with low testosterone in men.

Click here for more information on Unimed Pharmaceuticals, Inc. and to access Unimed's press release regarding this announcement.